Last reviewed · How we verify
Xeros
Xeros, developed by Grupo de Investigação em Bioquímica e Biologia Oral, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Xeros |
|---|---|
| Sponsor | Grupo de Investigação em Bioquímica e Biologia Oral |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Quality of Life and Sjögren Syndrome (PHASE4)
- Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeros CI brief — competitive landscape report
- Xeros updates RSS · CI watch RSS
- Grupo de Investigação em Bioquímica e Biologia Oral portfolio CI